Trends in Nonsurgical Management for Low-Risk, Hormone Receptor–Positive Ductal Carcinoma In Situ

What are the trends and patterns of nonsurgical management and other treatment modalities for low-risk, hormone receptor–positive ductal carcinoma in situ (DCIS) in the US?In this cross-sectional study of 316 590 patients with grade 1 to 2 DCIS, nonsurgical management and bilateral mastectomy increased from 2004 to 2022, adjuvant radiotherapy became genomic risk adapted since 2018, and endocrine therapy increased from 2004 to 2020 but declined thereafter. Sociodemographic variations were observed across treatment modalities.These findings highlight growing heterogeneity in DCIS management and the need for precision-prevention frameworks that align treatment intensity with cancer risk, patient preferences, and evolving evidence.

Corresponding Author: Dezheng Huo, MD, PhD, Department of Public Health Sciences, The University of Chicago, 5841 S Maryland Ave, MC2000, Chicago, IL 60637 (dhuo@bsd.uchicago.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.